7th Sep 2020 14:34
Destiny Pharma PLC - Brighton-based clinical stage biotechnology company - Developing Covid-19 prevention treatment alongside biotechnology firm SporeGen Ltd. Two companies will share costs and commercial returns of SPOR-COV product. Innovate UK has given GBP800,000 to fund most of GBP1 million cost of initial SPOR-COV programme.
Current stock price: 56.70
Year-to-date change: up 47%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DEST.L